Stada consolidates its commitment to biosimilars

The company The herds continues to consolidate its commitment to biosimilars with the marketing in Spain of Oyavas 25 mg / ml concentrate for solution for infusion, whose active ingredient is bevacizumab.

This biosimilar medicine is indicated for the treatment of various tumors such as lung, ovarian, renal cell, breast, cervical and colorectal cancer, in combination with other cancer drugs.

Biologics are changing the way cancer treatment is approached, but their high cost remains a significant barrier to access to treatments for many patients around the world. Biosimilars allow patients to access these treatments at a lower cost than the reference medicine while maintaining their efficacy and safety.

It is a biosimilar medicine indicated for the treatment of different tumors such as breast, colon, rectum, lung and ovarian cancer, in combination with other cancer medicines.

The presentation in Spain of the new biosimilar Oyavas is the result of the global partnership between Stada and the Spanish developer and manufacturer mAbxience. Oyavas, available in different countries of the European Union such as Germany and the Netherlands, expand the oncology portfolio specialized company in which other medications also stand out, such as bortezomib in a ready-to-use formulation for the treatment of myeloma and lymphoma.

“The launch of Oyavas demonstrates Stada’s purpose to be a partner reference to allow patient access to biosimilars “, says Mar Fábregas, general manager of Stada Spain.

“Stada continues to consolidate its commitment to a comprehensive portfolio of biosimilars, not only in oncology, but also in other therapeutic areas such as osteoporosis with the marketing of Movymia (teriparatide)”, emphasizes Fábregas.

Because we all need health … ConSalud.es

–